Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Momenta upgraded to Buy on increasing value of pipeline at Stifel

As previously reported, Stifel analyst Alex Schwartz upgraded Momenta to Buy from Hold, stating that he believes the company's progress in its novel pipeline outweighs the highly competitive marketplace for generic Copaxone.

He thinks January's M281 data that showed over 80% reduction in IgG level and a clean safety profile is "compelling" and that M281 is valuable, he tells investors, noting that he has now added the drug to his model.

Schwartz raised his price target on Momenta shares to $21 from $18.

Read more at:
https://thefly.com/landingPageNews.php?id=2687938